- Home
- WTI vs EDIT Comparison
WTI vs EDIT Comparison
Compare WTI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WTI | EDIT |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.4M | 233.3M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | WTI | EDIT |
|---|---|---|
| Price | $1.80 | $2.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,094,000.00 | $46,383,000.00 |
| Revenue This Year | $0.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $0.91 |
| 52 Week High | $2.59 | $4.54 |
Technical Indicators
Market Signals| Indicator | WTI | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 43.30 |
| Support Level | $1.64 | $2.09 |
| Resistance Level | $1.91 | $2.51 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 47.07 | 54.69 |
Price Performance
Historical ComparisonAbout WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.